ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2738

Differential Methylation of Peripheral Blood Adaptive Immune Cells in Individuals at High Risk for RA and with Early RA Compared with Controls Identifies Pathways Important in Transition to Arthritis

Rizi Ai1, David Boyle 2, Deepa Hammaker 3, Kevin Deane 4, V. Michael Holers 5, Andre Matti 6, William Robinson 7, Jane Buckner 8, Navin Rao 9, Frédéric Baribaud 10, George Vratsanos 11, Sunil Nagpal 9, Wei Wang 2 and Gary Firestein 3, 1University of California San Diego, San Diego, 2University of California, San Diego, San Diego, CA, 3University of California, San Diego, San Diego, 4University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, 5University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, 6UCSD, La Jolla, CA, 7Stanford University, Stanford, CA, 8Benaroya Research Institute, Seattle, WA, 9Janssen R&D, Spring House, PA, 10Janssen Research & Development, LLC, Spring House, PA, 11JNJ, Raritan, NJ

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: DNA Methylation, Epigenetics, rheumatoid arthritis (RA) and Peripheral blood

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T088: Genetics, Genomics & Proteomics (2738–2743)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing RA because of serum anti-citrullinated protein antibody positivity in absence of arthritis, and is focused on defining how they transition from at-risk to classifiable disease. One potential mechanism is through alterations in epigenetics patterns in adaptive immune cells. Previous studies showed that DNA methylation patterns of early RA (ERA) synoviocytes differ from long-standing RA, suggesting that abnormal methylation occurs early in synovium and evolves over time. To extend these observations, we performed a cross-sectional analysis in TIP-RA of DNA methylation signatures in peripheral blood cells in ERA, at-risk anti-CCP3+ individuals and demographically matched CCP- controls.

Methods: Genomic DNA was isolated from two independent cohorts of CCP- (cohorts 1 and 2, respectively: B cell: n = 17/34; memory T cell: n = 21/34; and naïve T cell: n = 21/33), CCP3+ (B cell: n = 18/37; memory T cell: n = 20/36; and naïve T cell: n = 20/35), and CCP3+ ERA (B cell: n = 4/18; memory T cell: n = 5/18; and naïve T cell: n = 5/18) after separating PBMCs using antibodies and magnetic beads. Methylation was measured by Illumina Infinium MethylationEPIC chip. Differentially methylated loci (DMLs) were identified using Welch’s t-test and mapped to gene promoter regions to define DM genes (DMGs). Principal component analysis (PCA) was used to represent relationship among groups. Pathway analysis was applied by Reactome.

Results: For the initial cohort, 1494, 1097 and 1330 DMLs were identified among CCP+, CCP- and ERA in B cells, memory T cells and naïve T cells, respectively. For the confirmatory cohort, 523, 793 and 548 DMLs were found in corresponding cell populations. The DML overlap between the 2 cohorts was highly significant (p= 2.48E-77). The DMLs were combined for both groups and corresponded to 411, 412, and 351 DMGs in B cells, memory T cells and naïve T cells. Of these, we found 246, 198 and 195 DMGs between CCP3+ and ERA in each peripheral blood cell population, respectively. PCA showed separation of CCP+, CCP- and ERA in each of the three blood cell types by DMLs (Fig. 1). DMGs were mapped to biological pathways to identify DM pathways. Although most were not significant, there were several highly significant differences comparing CCP+, ERA and CCP- in memory T cells involving pathways, including “Interferon gamma signaling” (FDR 7.48E-14), “PD-1 signaling” (FDR 8.71E-10), “Translocation of ZAP-70 to Immunological synapse” (FDR 4.75E-10), and “Phosphorylation of CD3 and TCR zeta chains” (FDR 8.71E-10).

Conclusion: We identified reproducible methylation signatures of CCP-, CCP+, and ERA in peripheral blood B cells, memory T cells and naïve T cells in initial and confirmatory cohorts. The methylome of ERA also demonstrated a distinctive pattern from CCP+, indicating that progression to RA is accompanied by epigenetic remodeling, especially in T cell signaling and interferon responses. These signatures identify critical pathways in CCP positivity and classifiable RA and could provide the basis of novel interventions to prevent disease.

Figure 1. PCA shows the separation of CCP+, CCP- and ERA patients in memory T cells based on DMLs in confirmatory cohort.


Disclosure: R. Ai, None; D. Boyle, Janssen, 2; D. Hammaker, None; K. Deane, Bristol-Myers Squibb, 5, Inova, 9, Janssen, 2, 5, Janssen R&D, 2, Microdrop, 5, Pfizer, 2; V. Holers, AdMIRx, 1, 2, 4, 5, 6, Alexion, 7, BMS, 5, Bristol-Myers Squibb, 5, Celgene, 5, Janssen R&D, 2, 5, Pfizer, 2; A. Matti, None; W. Robinson, None; J. Buckner, Bristol-Myers Squibb, 2, 5, Eli Lilly, 5, Janssen, 2, Novo Nordisk, 2, Pfizer, 2; N. Rao, Janssen Research & Development, 3, Johnson & Johnson, 1, 3, 4; F. Baribaud, Janssen Research & Development, LLC, 3; G. Vratsanos, Janssen Research & Development, 1, 3; S. Nagpal, Janssen Research & Development, 3, Janssen Research, Johnson&Johnson, 1, 3, 4, Johnson & Johnson, 1, 4; W. Wang, None; G. Firestein, Abbvie, 2, Janssen, 2.

To cite this abstract in AMA style:

Ai R, Boyle D, Hammaker D, Deane K, Holers V, Matti A, Robinson W, Buckner J, Rao N, Baribaud F, Vratsanos G, Nagpal S, Wang W, Firestein G. Differential Methylation of Peripheral Blood Adaptive Immune Cells in Individuals at High Risk for RA and with Early RA Compared with Controls Identifies Pathways Important in Transition to Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/differential-methylation-of-peripheral-blood-adaptive-immune-cells-in-individuals-at-high-risk-for-ra-and-with-early-ra-compared-with-controls-identifies-pathways-important-in-transition-to-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differential-methylation-of-peripheral-blood-adaptive-immune-cells-in-individuals-at-high-risk-for-ra-and-with-early-ra-compared-with-controls-identifies-pathways-important-in-transition-to-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology